KR102926889B1 - Cdk8/19 저해제 - Google Patents

Cdk8/19 저해제

Info

Publication number
KR102926889B1
KR102926889B1 KR1020217006527A KR20217006527A KR102926889B1 KR 102926889 B1 KR102926889 B1 KR 102926889B1 KR 1020217006527 A KR1020217006527 A KR 1020217006527A KR 20217006527 A KR20217006527 A KR 20217006527A KR 102926889 B1 KR102926889 B1 KR 102926889B1
Authority
KR
South Korea
Prior art keywords
unsubstituted
substituted
substituent
alkyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217006527A
Other languages
English (en)
Korean (ko)
Other versions
KR20210040416A (ko
Inventor
알레크세이 레오니도비치 민디치
안나 유레브나 체스트노바
마리아 안드레브나 카사트키나
안드레이 이바노비치 알라피노프
알렉세이 세르기비치 가브릴로프
안톤 알렉산드로비치 예브도키모프
릴리아나 비아체슬라보브나 렌슈미트
엘레나 알렉산드로브나 막시멘코
마리아 세르게브나 미시나
세르게이 알렉산드로비치 실로노프
에브게니 유레비치 스미르노프
파벨 안드리비치 야코프레브
드미트리 발렌티노비치 모로조프
Original Assignee
조인트 스탁 컴퍼니 “바이오케드”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조인트 스탁 컴퍼니 “바이오케드” filed Critical 조인트 스탁 컴퍼니 “바이오케드”
Publication of KR20210040416A publication Critical patent/KR20210040416A/ko
Application granted granted Critical
Publication of KR102926889B1 publication Critical patent/KR102926889B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217006527A 2018-08-03 2019-07-31 Cdk8/19 저해제 Active KR102926889B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19
RU2018128415 2018-08-03
PCT/RU2019/050123 WO2020027704A1 (ru) 2018-08-03 2019-07-31 Ингибиторы cdk8/19

Publications (2)

Publication Number Publication Date
KR20210040416A KR20210040416A (ko) 2021-04-13
KR102926889B1 true KR102926889B1 (ko) 2026-02-19

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217006527A Active KR102926889B1 (ko) 2018-08-03 2019-07-31 Cdk8/19 저해제

Country Status (19)

Country Link
US (1) US11840531B2 (https=)
EP (1) EP3831829A4 (https=)
JP (1) JP7365396B2 (https=)
KR (1) KR102926889B1 (https=)
CN (1) CN113166140B (https=)
AR (1) AR115898A1 (https=)
AU (1) AU2019313199B2 (https=)
BR (1) BR112021001939A2 (https=)
CA (1) CA3108298A1 (https=)
CL (1) CL2021000282A1 (https=)
CO (1) CO2021001174A2 (https=)
EA (1) EA202190452A1 (https=)
MA (1) MA52375B2 (https=)
MX (1) MX2021001335A (https=)
PE (1) PE20210416A1 (https=)
PH (1) PH12021550258A1 (https=)
RU (1) RU2761824C2 (https=)
TW (1) TWI839374B (https=)
WO (1) WO2020027704A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014768A1 (en) 2013-07-29 2015-02-05 F. Hoffmann-La Roche Ag 1,7-naphthyridine derivatives
US20160016951A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
WO2017202719A1 (en) 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
MX2010006244A (es) * 2007-12-06 2010-12-02 Schering Corp Moduladores de gamma secretasa.
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014768A1 (en) 2013-07-29 2015-02-05 F. Hoffmann-La Roche Ag 1,7-naphthyridine derivatives
US20160016951A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
WO2017202719A1 (en) 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Also Published As

Publication number Publication date
TW202012406A (zh) 2020-04-01
AU2019313199A1 (en) 2021-03-11
RU2018128415A (ru) 2020-02-04
PE20210416A1 (es) 2021-03-04
CO2021001174A2 (es) 2021-02-26
BR112021001939A2 (pt) 2021-04-27
MX2021001335A (es) 2021-04-12
CN113166140B (zh) 2024-06-14
CN113166140A (zh) 2021-07-23
EP3831829A1 (en) 2021-06-09
CL2021000282A1 (es) 2021-08-13
RU2761824C2 (ru) 2021-12-13
JP7365396B2 (ja) 2023-10-19
AR115898A1 (es) 2021-03-10
AU2019313199B2 (en) 2023-07-06
RU2018128415A3 (https=) 2021-03-30
EA202190452A1 (ru) 2021-04-13
US11840531B2 (en) 2023-12-12
MA52375B2 (fr) 2023-02-28
PH12021550258A1 (en) 2021-10-11
WO2020027704A1 (ru) 2020-02-06
TWI839374B (zh) 2024-04-21
MA52375A1 (fr) 2021-12-31
US20210246138A1 (en) 2021-08-12
EP3831829A4 (en) 2022-04-20
CA3108298A1 (en) 2020-02-06
KR20210040416A (ko) 2021-04-13
JP2021533143A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7832184B2 (ja) がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
KR102534962B1 (ko) 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물
EP3129380B1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
CN116209438A (zh) 使用sos1抑制剂治疗具有shp2突变的恶性疾病
JP7365332B2 (ja) Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
KR20180094939A (ko) 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
AU2021242143B2 (en) Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
TW202146416A (zh) 吡唑并三𠯤
KR102926889B1 (ko) Cdk8/19 저해제
RU2763347C2 (ru) Новые ингибиторы cdk8/19
RU2754441C2 (ru) Новые ингибиторы cdk8/19
EA042225B1 (ru) Ингибиторы cdk8/19
RU2852021C2 (ru) Новые ингибиторы JAK1-киназ
RU2851298C2 (ru) Новые ингибиторы JAK1-киназ
RU2739489C2 (ru) Новые гетероциклические соединения как ингибиторы CDK8/19
HK40058347A (en) Cdk8/19 inhibitors
HK40058347B (zh) Cdk8/19抑制剂
HK40086197A (zh) 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
TW202120511A (zh) 雜環化合物
EA041908B1 (ru) Производные 1,7-нафтиридина и их применение в качестве ингибиторов cdk8/19
BR112020002674B1 (pt) Compostos heterocíclicos como inibidoresde cdk8/19, método para inibir a atividade biológica de quinases de proteína, composição farmacêutica, método para tratamento de uma doença ou distúrbio e uso do composto ou sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)